Project description
Novel collagen VI-based bioactive wound dressing
Current available wound treatment options include the manipulation of multiple aspects of the wound environment but cannot form antibacterial barriers and facilitate efficient healing at the same time. The recent discovery of the healing and antimicrobial properties of human collagen VI enabled the development of a product with the potential to improve wound management. The Swedish company Colzyx aims to address the unmet challenges in wound management with its novel bioactive wound dressing product, that both accelerates wound healing and at the same time exhibits clear antibacterial effects. This approach promises significant benefits to patients, reducing pain and discomfort and accelerating the recovery process. The current objective of the EU-funded WOUNDCOM project is to validate the efficacy and safety of the new wound dressing and bring it to commercial readiness.
Objective
Chronic wounds are a global problem. They severely impair the quality of life for 200 million patients worldwide and generate vast medical costs. It is a problem that will only escalate with the increasing incidence of conditions that impede wound healing, such as diabetes, obesity and vascular disorders. The available wound care options can manipulate one or multiple aspects of the wound environment but cannot form antibacterial barriers and facilitate healing to a satisfactory level at the same time. Effective wound care products to address both: rapid wound closure and combat of infection are, therefore, urgently needed. Colzyx aims to address the unmet challenges in wound management with its novel wound dressing. Basing on a ground-breaking discovery of wound healing and antimicrobial properties of human collagen VI and parts thereof, Colzyx has developed a product that has the potential to revolutionise
wound management and create a new category of bioactive wound dressings. WOUNDCOM uses highly functional molecules that promote wound healing by mimicking natural body mechanisms and at the same time combat bacterial infection. This approach offers significant benefits to patients through reduction of pain and discomfort and accelerated recovery. It will also shorten hospitalisation
time and decrease the associated financial burden. This project’s objective is to validate the efficacy and safety of WOUNDCOM and bring it to commercial readiness. The project builds on our SMEi Phase 1 project, which provided a valuable understanding of the current trends and opportunities on the wound management market, targeted users, competitors and potential partnerships. The feasibility study was used to optimise the business plan and prepare a synopsis for the clinical study. Successful evaluation of WOUNDCOM’s in the
clinic will enable CE marking and support building the awareness and continued strategic partnerships for product manufacturing, marketing, and distribution.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
223 81 Lund
Sweden
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.